iRadimed (IRMD) Expected to Announce Quarterly Earnings on Monday

iRadimed (NASDAQ:IRMD) is expected to announce its Q1 2026 results before the market opens on Monday, May 4th. Analysts expect the company to announce earnings of $0.45 per share and revenue of $21.3150 million for the quarter. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. Interested persons may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Monday, May 4, 2026 at 9:00 AM ET.

iRadimed (NASDAQ:IRMD) last posted its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $0.54 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.05. The company had revenue of $22.69 million for the quarter, compared to analysts’ expectations of $21.60 million. iRadimed had a net margin of 26.82% and a return on equity of 23.83%. On average, analysts expect iRadimed to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

iRadimed Stock Performance

NASDAQ:IRMD opened at $88.68 on Monday. The stock has a market capitalization of $1.13 billion, a PE ratio of 50.67 and a beta of 1.11. The firm’s 50 day moving average is $97.93 and its 200 day moving average is $93.83. iRadimed has a 12 month low of $50.31 and a 12 month high of $107.90.

iRadimed Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, March 6th. Investors of record on Monday, February 23rd were issued a $0.20 dividend. This is a boost from iRadimed’s previous quarterly dividend of $0.17. The ex-dividend date of this dividend was Monday, February 23rd. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. iRadimed’s payout ratio is presently 45.71%.

Insider Transactions at iRadimed

In other iRadimed news, CEO Roger E. Susi sold 2,500 shares of the business’s stock in a transaction on Tuesday, April 21st. The shares were sold at an average price of $90.94, for a total transaction of $227,350.00. Following the sale, the chief executive officer owned 2,202,500 shares of the company’s stock, valued at $200,295,350. The trade was a 0.11% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 45,000 shares of company stock worth $4,374,600. Insiders own 36.80% of the company’s stock.

Institutional Investors Weigh In On iRadimed

Hedge funds and other institutional investors have recently bought and sold shares of the business. PharVision Advisers LLC bought a new stake in iRadimed during the 3rd quarter valued at $257,000. Boothbay Fund Management LLC bought a new stake in iRadimed during the 3rd quarter valued at $279,000. Creative Planning bought a new stake in iRadimed during the 3rd quarter valued at $315,000. Osaic Holdings Inc. raised its holdings in iRadimed by 766.6% during the 2nd quarter. Osaic Holdings Inc. now owns 3,813 shares of the medical equipment provider’s stock valued at $228,000 after acquiring an additional 3,373 shares during the period. Finally, Brevan Howard Capital Management LP bought a new stake in iRadimed during the 2nd quarter valued at $260,000. Institutional investors own 92.34% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently commented on IRMD. Roth Mkm reaffirmed a “buy” rating and issued a $120.00 price target on shares of iRadimed in a report on Tuesday, February 10th. Lake Street Capital reaffirmed a “buy” rating and issued a $120.00 price target on shares of iRadimed in a report on Wednesday, February 11th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of iRadimed in a report on Monday, December 29th. Finally, Freedom Capital raised shares of iRadimed to a “strong-buy” rating in a report on Thursday, April 2nd. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, iRadimed presently has an average rating of “Buy” and an average price target of $120.00.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.